Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Intellia Therapeutics Logo Intellia Therapeutics Logo John Leonard, M.D., President and CEO, Intellia Therapeutics John…
Canopy Secures $22M Series B to Define the Standard for Connected Safety and Location Intelligence